Deena Kuruvilla
Neurology · Westport, CTNPI 1588975429
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $315,979 of the $439,848 with a category attached, or 71.8%. 14 manufacturers reported payments, led by Lilly USA, LLC at 46.3% of the total. Reporting peaked in 2022 at $112,266 and has fallen 51.9% since, to $54,026 in 2025. Among neurology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 610 payments — averaging $721.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$204K
- AbbVie$188K
- Pfizer$25K
- Amgen$20K
- Biohaven Pharmaceuticals, Inc.$2K
- Lundbeck LLC$330
- plus $730 from 8 others
What the payments were for
- Consulting fees$75,43517%
- Speaking & faculty fees$315,97972%
- Grants$880%
- Travel & lodging$36,7518%
- Food & beverage$11,4283%
- Education$1680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 307 | $203,602 |
| AbbVie(2 entities) | 205 | $187,604 |
| Pfizer | 29 | $25,256 |
| Amgen | 31 | $19,860 |
| Biohaven Pharmaceuticals, Inc. | 9 | $2,467 |
| Lundbeck LLC | 8 | $330 |
| Teva Pharmaceuticals USA, Inc. | 9 | $228 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $186 |
| Impel Pharmaceuticals Inc. | 1 | $98 |
| Eli Lilly | 1 | $87 |
| Axsome Therapeutics, Inc. | 2 | $55 |
| Upsher-smith Laboratories LLC | 2 | $33 |
| Bausch Health US, LLC | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$439,848 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 11 | $44,790 |
| QuliptaAtogepant | 13 | $34,341 |
| Tizanidine Hcl | 17 | $631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $187,604 | $79,13124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 neurology providers in Connecticut.
Other neurology in Westport
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Duarte MachadoCheshire$426K
- Tanya BilchikEast Hartford$361K
- Peter GottschalkFairfield$318K
- Joseph GuarnacciaDerby$304K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.